The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
The authors report the results of the phase II PEMDAC clinical study testing the combination of the HDAC inhibitor entinostat with the anti- PD-1 antibody pembrolizumab in uveal melanoma. Low tumor burden, a wildtype BAP1 gene in the tumor or iris melanoma correlates with response and longer surviva...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-25332-w |